Table 1 The clinical and genetic features of TCGA and BeatAML cohorts
From: The landscape of gene co-expression modules correlating with prognostic genetic abnormalities in AML
| Â | BeatAML | TCGA |
|---|---|---|
Patient number | 421 | 136 |
Female/male | 180/241 | 61/75 |
Median age (yr) | 61 | 58 |
Relapsed disease | 23(5.46%) | NA |
MDS history | 41(9.74%) | NA |
ELN2017 risk stratification | ||
 Favorable | 101(24.0%) | 17(12.5%) |
 Intermediate | 156(37.1%) | 80(58.8%) |
 Poor | 163(38.7%) | 36(26.5%) |
 Unknown | 1(0.2%) | 3(2.7%) |
ELN2017 prognostic markers | ||
 Complex karyotype | 69(16.4%) | 18(13.2%) |
 del(7) | 6(1.4%) | NA |
 RUNX1-RUNX1T1 | 11(2.6%) | 6(4.4%) |
 CBFB-MYH11 | 10(2.4%) | 8(5.9%) |
 CEBPA_Biallelic | 7(1.7%) | 13(9.6%) |
 MLLT3-KMT2A | 13(3.1%) | 2(1.5%) |
 DEK-NUP214 | 3(0.7%) | NA |
 GATA2-MECOM | 8(1.9%) | NA |
 FLT3-ITD | 95(22.6%) | 38(27.9%) |
 NPM1 | 108(25.7%) | 38(27.9%) |
 ASXL1 | 31(7.4%) | 2(1.5%) |
 RUNX1 | 32(7.6%) | 14(10.3%) |
 TP53 | 27(6.4%) | 11(8.1%) |
 5- or del(5q) | NA | 3(2.2%) |
 NPM1 (+) FLT3-ITD (−) | 59 | NA |
 NPM1 (+) FLT3-ITD ( +) | 49 | NA |
 NPM1 (−) FLT3-ITD (−) | 100 | NA |
 NPM1 (−) FLT3-ITD ( +) | 46 | NA |